Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEX101 in Relapsed/Refractory B-Cell Lymphoma
NCT07882641Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of BEX101 in non-Hodgkin lymphoma (NHL), sponsored by Chinese PLA General Hospital. Started Oct 2026; status: recruiting.
02
Drugs
BEX101
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07882641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07882641.